Companies
/
Evidation
Healthtech
Evidation is a San Mateo-based health technology company that uses data from wearables and smartphones, combined with participant engagement, to run research studies and generate real-world health insights.
Create an account to view live offerings, pricing, and market activity.
Sign in to view offerings and live market activity.
Evidation was founded in 2012 by Christine Lemke and Deborah Kilpatrick, based on the recognition that the proliferation of wearable devices, smartphones, and other connected health technologies had created an enormous, largely untapped opportunity to passively and continuously measure real-world health-related behaviors, such as physical activity, sleep patterns, and other digital biomarkers, at a scale and level of granularity that traditional clinical research methods, which typically rely on periodic in-person visits and self-reported questionnaires, could not easily capture. Evidation's platform recruits and engages a very large member base of individuals who opt in to share data from their wearable devices, smartphones, and other connected health technologies, along with completing surveys and other study activities, in exchange for modest rewards and the ability to contribute to health research, building one of the largest real-world, technology-enabled research cohorts of its kind. The company partners with pharmaceutical companies, medical device manufacturers, academic researchers, and government health agencies to design and run research studies using this data, ranging from studies exploring how digital biomarkers might help detect or predict various health conditions earlier than traditional methods, to studies evaluating how well specific treatments or interventions work in real-world conditions outside the more controlled and artificial environment of a traditional clinical trial. During the COVID-19 pandemic, Evidation's platform was used in notable research efforts exploring whether data from wearable devices, such as changes in resting heart rate or activity patterns, could help detect early signs of COVID-19 infection before symptoms became apparent, an example of the kind of real-world, passively collected health data research the company specializes in enabling. Evidation has raised substantial venture funding from investors including Rock Springs Capital, Sanofi, and B Capital, positioning itself at the intersection of digital health, real-world evidence research, and pharmaceutical and medical research partnerships.
FOR QUALIFIED INSTITUTIONAL AND ACCREDITED INVESTORS ONLY: Under federal securities laws, private market investments on this platform are available exclusively to Institutional and Accredited Investors. Verification of status required before investing. Private investments involve significant risks including illiquidity, potential loss of principal, and limited disclosure requirements. "Augment" refers to Augment Markets, Inc. and its affiliates. Augment Markets, Inc. is a technology company offering software and data services, not a bank or financial institution. Cash Accounts are provided by Modern Treasury Corp. financial institution partners and through Augment's technology. Augment does not act as a money services business, provide money transmission, or serve as a custodian of funds. Funds held in your Cash Account are not FDIC insured unless expressly disclosed. Full terms available in the Augment Cash Account Agreement. Brokerage services are offered through Augment Capital, LLC, an affiliated broker-dealer and member FINRA/SIPC. "Investment accounts" are not brokerage accounts and do not hold customer funds or securities. Investment advisory services are offered through Augment Advisors, LLC, an SEC-registered investment adviser. Registration with the SEC does not imply a certain level of skill or training. Neither Augment Advisors, LLC nor Augment Capital, LLC provide legal or tax advice; consult your attorney or tax professional regarding your specific situation. For additional information, please refer to Augment Advisors, LLC's Form ADV Part 2A (Firm Brochure) and FINRA BrokerCheck.
No news available for this company.
